Losartan
- Generic Name
- Losartan
- Brand Names
- Hyzaar, Cozaar
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23ClN6O
- CAS Number
- 114798-26-4
- Unique Ingredient Identifier
- JMS50MPO89
- Background
Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Los...
- Indication
Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hyper...
- Associated Conditions
- Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
- Associated Therapies
- -
Losartan in Prevention of Radiation-Induced Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT05607017
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Hospital General de Niños Pedro de Elizalde
- Target Recruit Count
- 40
- Registration Number
- NCT05402397
- Locations
- 🇦🇷
HGNPE, Caba, Argentina
Cardiorenal Effecs of Losartan in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Medical University of Gdansk
- Target Recruit Count
- 740
- Registration Number
- NCT05243446
- Locations
- 🇵🇱
Medical University, Gdansk, Poland
Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT05157464
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Effects of Angiotensin Converting Enzyme Inhibitors on Patency of Arterio-Venous Fistulas: A Randomized Controlled Trial
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2021-11-24
- Target Recruit Count
- 100
- Registration Number
- NCT05132712
- Locations
- 🇵🇰
Anas Bin Saif, Rawalpindi, Punjab, Pakistan
Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 52
- Registration Number
- NCT05097248
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College of HUST, Wuhan, Hubei, China
FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Colin D. Weekes, M.D., PhD
- Target Recruit Count
- 70
- Registration Number
- NCT05077800
- Locations
- 🇺🇸
Univesity of Colorado, Aurora, Colorado, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸University of Washington, Seattle, Washington, United States
Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 24
- Registration Number
- NCT05012631
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
- Conditions
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 100
- Registration Number
- NCT04815902
- Locations
- 🇺🇸
The Steadman Clinic, Vail, Colorado, United States
Secondhand Tobacco Smoke and Cardiovascular Disease
- Conditions
- Interventions
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 100
- Registration Number
- NCT04715568
- Locations
- 🇺🇸
San Francisco Veterans' Affairs Medical Center, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.